TEVA PHARMACEUTICAL INDUSTRIES LTD: MENORA MIVTACHIM HOLDINGS LTD. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Menora Mivtachim Holdings Ltd. amended its Schedule 13G filing on Teva Pharmaceutical Industries Ltd., updating its beneficial ownership stake with the U.S. Securities and Exchange Commission under accession number 0001178913-26-005117. The filing reflects a change in the Israeli insurer and asset manager's position in the generic-drug maker, though the amended document did not immediately disclose the revised share count or percentage. Schedule 13G amendments are typically filed by passive investors when their holdings cross or move meaningfully above the 5% threshold, making the update a signal of Menora's shifting exposure to Teva. Investors will watch for the specific stake size in the amended filing and any subsequent 13G or 13D activity from other institutional holders. Teva shares remain sensitive to institutional ownership changes given the company's ongoing debt-reduction efforts and generic-drug pricing pressures.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Teva Pharmaceutical Industries Ltd., Menora Mivtachim Holdings Ltd.